DnaJB6 is present in the core of Lewy bodies and is highly up-regulated in Parkinsonian astrocytes

Journal of Neuroscience Research

Volumn 87, Issue 1, 2009, Pages 238-245

  Durrenberger, P F ^a,e   Filiou, M D ^a,e   Moran, L B ^a,e   Michael, G J ^b   Novoselov, S ^c   Cheetham, M E ^c   Clark, P ^d   Pearce, R K B ^a,e   Graeber, Manuel B ^a,e,f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^f The Athenaeum   (United Kingdom)

Author keywords

Alpha synucleinopathies; Glia; Heat shock proteins; Molecular chaperones; Neurodegeneration; Protein deposition disorders

Indexed keywords

ALPHA SYNUCLEIN; MESSENGER RNA; PROTEIN DNAJ; PROTEIN DNAJB6; UNCLASSIFIED DRUG;

AGED; ARTICLE; ASTROCYTE; BRAIN CORTEX; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GLIA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEWY BODY; MALE; NEUROPATHOLOGY; NEUROPROTECTION; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ASTROCYTES; FEMALE; HSP40 HEAT-SHOCK PROTEINS; HUMANS; LEWY BODIES; MALE; MOLECULAR CHAPERONES; NERVE TISSUE PROTEINS; PARKINSONIAN DISORDERS; POSTMORTEM CHANGES; RNA, MESSENGER; UP-REGULATION;

EID: 62049084346     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21819     Document Type: Article

References (32)

1. Boyault C, Zhang Y, Fritah S, Caron C, Gilquin B, Kwon SH, Garrido C, Yao TP, Vourc'h C, Matthias P, Khochbin S. 2007. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 21:2172-2181.
2. Braak H, Sastre M, Del Tredici K. 2007. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol 114:231-241.
3. Cheetham ME, Brion JP, Anderton BH. 1992. Human homologues of the bacterial heat-shock protein DnaJ are preferentially expressed in neurons. Biochem J 284:469-476.
4. Chuang JZ, Zhou H, Zhu M, Li SH, Li XJ, Sung CH. 2002., Characterization of a brain-enriched chaperone, MRJ, that inhibits Huntingtin aggregation and toxicity independently. J Biol Chem 277:19831-19838.
5. Dai YS, Xu J, Molkentin JD. 2005. The DnaJ-related factor Mrj interacts with nuclear factor of activated T cells c3 and mediates transcriptional repression through class II histone deacetylase recruitment. Mol Cell Biol 25:9936-9948.
6. Duke DC, Moran LB, Kalaitzakis ME, Deprez M, Dexter DT, Pearce RK, Graeber MB. 2006. Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics 7:139-148.
7. Fayazi Z, Ghosh S, Marion S, Bao X, Shero M, Kazemi-Esfarjani P. 2006. A Drosophila ortholog of the human MRJ modulates polyglutamine toxicity and aggregation. Neurobiol Dis 24:226-244.
8. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC. 2000. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 97:2875-2880.
9. Jayanthi S, Deng X, Ladenheim B, McCoy MT, Cluster A, Cai NS, Cadet JL. 2005. Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc Natl Acad Sci U S A 102:868-873.
10. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. 2003. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727-738.
11. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. 2004. Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem 279: 25497-25502.
12. Kontopoulos E, Parvin JD, Feany MB. 2006. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15:3012-3023.
13. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y. 1988. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol 75:345-353.
14. Lee SJ. 2008. Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J Mol Neurosci 34:17-22.
15. Lu L, Neff F, Alvarez-Fischer D, Henze C, Xie Y, Oertel WH, Schlegel J, Hartmann A. 2005. Gene expression profiling of Lewy body-bearing neurons in Parkinson's disease. Exp Neurol 195:27-39.
16. Michael GJ, Averill S, Nitkunan A, Rattray M, Bennett DL, Yan Q, Priestley JV. 1997. Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J Neurosci 17:8476-8490.
17. Mirza B, Hadberg H, Thomsen P, Moos T. 2000. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95:425-432.
18. Moran LB, Graeber MB. 2008. Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation. Neurogenetics 9:1-13.
19. Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RK, Graeber MB. 2006. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 7:1-11.
20. Moran LB, Hickey E, Michael GJ, Derkacs M, Christian LM, Kalaitzakis ME, Pearce RK, Graeber MB. 2008. Neuronal pentraxin II is highly up-regulated in Parkinson's disease and a novel component of Lewy bodies. Acta Neuropathol 115:471-478.
21. Olanow CW, Perl DP, DeMartino GN, McNaught KS. 2004. Lewybody formation is an aggresome-related process: a hypothesis. Lancet Neurol 3:496-503.
22. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH, Taylor JP. 2007. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447:859-863.
23. Peirson SN, Butler JN, Foster RG. 2003. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 31:e73.
24. Qiu XB, Shao YM, Miao S, Wang L. 2006. The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci 63:2560-2570.
25. Rochet JC. Novel therapeutic strategies for the treatment of protein-misfolding diseases. 2007. Expert Rev Mol Med 9:1-34.
26. Shults CW. 2006. Lewy bodies. Proc Natl Acad Sci U S A 103:1661-1668.
27. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95:6469-6473.
28. Takahashi-Fujigasaki J, Fujigasaki H. 2006. Histone deacetylase (HDAC) 4 involvement in both Lewy and Marinesco bodies. Neuropathol Appl Neurobiol 32:562-566.
29. Terada S, Ishizu H, Yokota O, Tsuchiya K, Nakashima H, Ishihara T, Fujita D, Ueda K, Ikeda K, Kuroda S. 2003. Glial involvement in diffuse Lewy body disease. Acta Neuropathol 105:163-169.
30. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. 2000. NACP/ alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol 99: 14-20.
31. Watson ED, Geary-Joo C, Hughes M, Cross JC. 2007. The Mrj cochaperone mediates keratin turnover and prevents the formation of toxic inclusion bodies in trophoblast cells of the placenta. Development 134:1809-1817.
32. Westhoff B, Chapple JP, van der Spuy J, Hohfeld J, Cheetham ME. 2005. HSJ1 is a neuronal shuttling factor for the sorting of chaperone clients, to the proteasome. Curr Biol 15:1058-1064.